Dr.inB Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
10
- Latest Deal Type
-
Accelerator/Inc
- Investors
-
6
Dr.inB General Information
Description
Developer of a laser therapy device designed to treat tumors. The company's therapy uses photodynamic (PDT) technology and a new drug substance that responds to light, enabling healthcare industry to take care of skin health.
Contact Information
Website
www.drinb.co.krCorporate Office
- Number 502,151 Gyejok-Ro
- Dong Gu
- Daejeon
- South Korea
Corporate Office
- Number 502,151 Gyejok-Ro
- Dong Gu
- Daejeon
- South Korea
Dr.inB Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Accelerator/Incubator | Completed | Clinical Trials - General | ||||
| 4. Later Stage VC | 18-Jan-2024 | Completed | Clinical Trials - General | |||
| 3. Early Stage VC | 14-Jul-2022 | Completed | Clinical Trials - General | |||
| 2. Accelerator/Incubator | 28-Feb-2022 | Completed | Clinical Trials - General | |||
| 1. Seed Round | 01-Jul-2020 | Completed | Clinical Trials - General |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Dr.inB Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Dr.inB Patents
Dr.inB Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023140629-A1 | 2,7-substituted pyrrolo[2,1-f][1,2,4]triazine compound having protein kinase inhibitory activity | Inactive | 20-Jan-2022 | ||
| WO-2023085567-A1 | Method for preparing medicines, having reduced production time and improved stability | Inactive | 12-Nov-2021 | ||
| WO-2023068423-A1 | Complex anticancer drug composition using photoreactivity and preparation method therefor | Inactive | 21-Oct-2021 | A61K41/0057 |
Dr.inB Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Dr.inB Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Hanlim Pharm | Corporation | Minority | ||
| MMS Ventures (Korea) | Venture Capital | Minority | ||
| Tech Incubator Program for Startup | Accelerator/Incubator | |||
| Korea Science & Technology Holdings | Venture Capital | Minority | ||
| WooGene B&G | Corporation | Minority |
Dr.inB FAQs
-
When was Dr.inB founded?
Dr.inB was founded in 2019.
-
Where is Dr.inB headquartered?
Dr.inB is headquartered in Daejeon, South Korea.
-
What is the size of Dr.inB?
Dr.inB has 10 total employees.
-
What industry is Dr.inB in?
Dr.inB’s primary industry is Other Devices and Supplies.
-
Is Dr.inB a private or public company?
Dr.inB is a Private company.
-
What is Dr.inB’s current revenue?
The current revenue for Dr.inB is .
-
Who are Dr.inB’s investors?
Hanlim Pharm, MMS Ventures (Korea), Tech Incubator Program for Startup, Korea Science & Technology Holdings, and WooGene B&G are 5 of 6 investors who have invested in Dr.inB.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
